JP2016512227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512227A5 JP2016512227A5 JP2015562523A JP2015562523A JP2016512227A5 JP 2016512227 A5 JP2016512227 A5 JP 2016512227A5 JP 2015562523 A JP2015562523 A JP 2015562523A JP 2015562523 A JP2015562523 A JP 2015562523A JP 2016512227 A5 JP2016512227 A5 JP 2016512227A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ethyl
- hydroxyacetamide
- oxadiazol
- hydroxypropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- -1 penta-3-yl Chemical group 0.000 claims 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- GXTJJKTVNPGWLJ-IBGZPJMESA-N n-[(2s)-3-[2-ethyl-4-[5-(2-ethylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound C1=NC(CC)=CC(C=2ON=C(N=2)C=2C=C(CC)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1 GXTJJKTVNPGWLJ-IBGZPJMESA-N 0.000 claims 1
- BUMUZYJYGCXMOQ-IBGZPJMESA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-(2-propan-2-ylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=CC=2)C(C)C)=C1 BUMUZYJYGCXMOQ-IBGZPJMESA-N 0.000 claims 1
- VYUYMNNZGDEJLE-FQEVSTJZSA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-(2-propylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound C1=NC(CCC)=CC(C=2ON=C(N=2)C=2C=C(CC)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1 VYUYMNNZGDEJLE-FQEVSTJZSA-N 0.000 claims 1
- FIZLCOHGMMUGTO-NRFANRHFSA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-[2-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(CC(C)C)N=CC=2)=C1 FIZLCOHGMMUGTO-NRFANRHFSA-N 0.000 claims 1
- PFJWQQDDQKRIRR-QFIPXVFZSA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-[2-(3-methylbutyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(CCC(C)C)N=CC=2)=C1 PFJWQQDDQKRIRR-QFIPXVFZSA-N 0.000 claims 1
- DIVNEVSXGMFTRK-NRFANRHFSA-N n-[(2s)-3-[4-[5-(2-butylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound C1=NC(CCCC)=CC(C=2ON=C(N=2)C=2C=C(CC)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1 DIVNEVSXGMFTRK-NRFANRHFSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13159482.2 | 2013-03-15 | ||
| EP13159482 | 2013-03-15 | ||
| PCT/IB2014/059794 WO2014141171A1 (en) | 2013-03-15 | 2014-03-14 | Pyridin-4-yl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512227A JP2016512227A (ja) | 2016-04-25 |
| JP2016512227A5 true JP2016512227A5 (2) | 2017-03-30 |
| JP6387361B2 JP6387361B2 (ja) | 2018-09-05 |
Family
ID=47877933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562523A Expired - Fee Related JP6387361B2 (ja) | 2013-03-15 | 2014-03-14 | ピリジン−４−イル誘導体 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9617250B2 (2) |
| EP (1) | EP2970236B1 (2) |
| JP (1) | JP6387361B2 (2) |
| KR (1) | KR102212975B1 (2) |
| CN (1) | CN105189487B (2) |
| AR (1) | AR095523A1 (2) |
| AU (1) | AU2014229217B2 (2) |
| BR (1) | BR112015023161B1 (2) |
| CA (1) | CA2900910C (2) |
| CL (1) | CL2015002620A1 (2) |
| CY (1) | CY1119619T1 (2) |
| DK (1) | DK2970236T3 (2) |
| EA (1) | EA029309B1 (2) |
| ES (1) | ES2649475T3 (2) |
| HR (1) | HRP20171763T1 (2) |
| HU (1) | HUE035154T2 (2) |
| IL (1) | IL241363B (2) |
| LT (1) | LT2970236T (2) |
| MA (1) | MA38482B1 (2) |
| MX (1) | MX363545B (2) |
| MY (1) | MY173573A (2) |
| NO (1) | NO2970236T3 (2) |
| NZ (1) | NZ713080A (2) |
| PH (1) | PH12015502118B1 (2) |
| PL (1) | PL2970236T3 (2) |
| PT (1) | PT2970236T (2) |
| SA (1) | SA515361104B1 (2) |
| SG (1) | SG11201507227UA (2) |
| SI (1) | SI2970236T1 (2) |
| TW (1) | TWI623534B (2) |
| UA (1) | UA115357C2 (2) |
| WO (1) | WO2014141171A1 (2) |
| ZA (1) | ZA201507657B (2) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| PH12017502097B1 (en) | 2015-05-20 | 2023-05-05 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| WO2017004610A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| PT2069336E (pt) * | 2006-09-07 | 2013-03-07 | Actelion Pharmaceuticals Ltd | Derivados de piridin-4-ilo como agentes imunomoduladores |
| PL2069335T3 (pl) | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| ES2393412T3 (es) | 2006-09-21 | 2012-12-21 | Actelion Pharmaceuticals Ltd. | Derivados de fenilo y su uso como inmunomoduladores |
| BRPI0808789A2 (pt) | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
| PT2195311E (pt) | 2007-08-17 | 2011-05-25 | Actelion Pharmaceuticals Ltd | Derivados de piridina como moduladores do receptor s1p1/edg1 |
| MX2010003612A (es) | 2007-10-04 | 2010-04-30 | Merck Serono Sa | Derivados de oxadiazol. |
| KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
| WO2009109907A1 (en) | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel pyrimidine-pyridine derivatives |
| EP2262799B1 (en) | 2008-03-06 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Pyridine compounds |
| CA2715317A1 (en) | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| WO2009109872A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
| EP3782991A1 (en) * | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| ES2517265T3 (es) | 2009-03-03 | 2014-11-03 | Merck Serono S.A. | Derivados de oxadiazol piridina |
| CA2767585C (en) | 2009-07-16 | 2017-09-26 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| MA34910B1 (fr) | 2011-01-19 | 2014-02-01 | Actelion Pharmaceuticals Ltd | Dérivés de 2-methoxy-pyridin-4-yl |
-
2014
- 2014-03-14 NZ NZ713080A patent/NZ713080A/en not_active IP Right Cessation
- 2014-03-14 NO NO14715427A patent/NO2970236T3/no unknown
- 2014-03-14 SI SI201430428T patent/SI2970236T1/sl unknown
- 2014-03-14 WO PCT/IB2014/059794 patent/WO2014141171A1/en not_active Ceased
- 2014-03-14 JP JP2015562523A patent/JP6387361B2/ja not_active Expired - Fee Related
- 2014-03-14 PL PL14715427T patent/PL2970236T3/pl unknown
- 2014-03-14 CA CA2900910A patent/CA2900910C/en active Active
- 2014-03-14 EP EP14715427.2A patent/EP2970236B1/en active Active
- 2014-03-14 EA EA201500931A patent/EA029309B1/ru not_active IP Right Cessation
- 2014-03-14 AR ARP140101131A patent/AR095523A1/es active IP Right Grant
- 2014-03-14 DK DK14715427.2T patent/DK2970236T3/en active
- 2014-03-14 BR BR112015023161-6A patent/BR112015023161B1/pt not_active IP Right Cessation
- 2014-03-14 LT LTEP14715427.2T patent/LT2970236T/lt unknown
- 2014-03-14 KR KR1020157028486A patent/KR102212975B1/ko not_active Expired - Fee Related
- 2014-03-14 MX MX2015012293A patent/MX363545B/es unknown
- 2014-03-14 US US14/777,444 patent/US9617250B2/en active Active
- 2014-03-14 CN CN201480016238.1A patent/CN105189487B/zh not_active Expired - Fee Related
- 2014-03-14 SG SG11201507227UA patent/SG11201507227UA/en unknown
- 2014-03-14 HR HRP20171763TT patent/HRP20171763T1/hr unknown
- 2014-03-14 MA MA38482A patent/MA38482B1/fr unknown
- 2014-03-14 UA UAA201510003A patent/UA115357C2/uk unknown
- 2014-03-14 PT PT147154272T patent/PT2970236T/pt unknown
- 2014-03-14 ES ES14715427.2T patent/ES2649475T3/es active Active
- 2014-03-14 TW TW103109288A patent/TWI623534B/zh not_active IP Right Cessation
- 2014-03-14 AU AU2014229217A patent/AU2014229217B2/en not_active Ceased
- 2014-03-14 HU HUE14715427A patent/HUE035154T2/en unknown
- 2014-03-14 MY MYPI2015703154A patent/MY173573A/en unknown
-
2015
- 2015-09-09 IL IL241363A patent/IL241363B/en active IP Right Grant
- 2015-09-11 CL CL2015002620A patent/CL2015002620A1/es unknown
- 2015-09-14 PH PH12015502118A patent/PH12015502118B1/en unknown
- 2015-09-14 SA SA515361104A patent/SA515361104B1/ar unknown
- 2015-10-14 ZA ZA2015/07657A patent/ZA201507657B/en unknown
-
2017
- 2017-11-24 CY CY20171101239T patent/CY1119619T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512227A5 (2) | ||
| US20250122188A1 (en) | Modulators of the integrated stress pathway | |
| HRP20171763T1 (hr) | Derivati piridin-4-ila | |
| JP2017509689A5 (2) | ||
| JP2017524735A5 (2) | ||
| JP2016536286A5 (2) | ||
| JP2015024998A5 (2) | ||
| JP2016532667A5 (2) | ||
| JP2019501130A5 (2) | ||
| JP2013537203A5 (2) | ||
| JP2014511891A5 (2) | ||
| JP2014523851A5 (2) | ||
| JP2016510326A5 (2) | ||
| JP2013542261A5 (2) | ||
| JP2017527561A5 (2) | ||
| JP2017505762A5 (2) | ||
| JP2012530137A5 (2) | ||
| JP2015505296A5 (2) | ||
| JP2016040288A5 (2) | ||
| JP2018534355A5 (2) | ||
| JP2017517512A5 (2) | ||
| US11612604B2 (en) | Methods of treating cancer with PLK4 inhibitors | |
| JP2016508506A5 (2) | ||
| JP2017522277A5 (2) | ||
| JP2019520344A5 (2) |